Gritstone bio(US:GRTS)2021-11-23 13:10Financial Status - Gritstone reported a cash position of approximately $216.4 million as of September 30, 2021 [4] - Research and Development expenses were $24.4 million for the three months ended September 30, 2021 [80] - General and Administrative expenses totaled $6.4 million for the three months ended September 30, 2021 [80] Pipeline Programs & Milestones - CORAL COVID-19 vaccine program targets spike protein + T cell Epitopes (TCE) [11] with Q1 2022 data expected from a booster trial in individuals aged 60+ [8, 81] and 1H 2022 data from a NIAID sponsored trial [8, 13] - Gritstone and Gilead are collaborating to develop an HIV-specific therapeutic vaccine, with a deal value of up to $785 million plus royalties [33] - GRANITE, an individualized neoantigen therapy, showed a 44% molecular response as measured by ctDNA reduction [41] - Phase 2 trial initiations in MSS-CRC for GRANITE are planned for 1H 2022, including 1L maintenance (Q1) and adjuvant settings (Q2) [42] - SLATE, an off-the-shelf neoantigen therapy, demonstrated ctDNA responses in 66% of patients with the KRASmut G12C-HLA A*02:01 complex [68] Technology & Platform - Gritstone's EDGE AI platform is used for target identification, with >70% Positive Predictive Value [3, 9] - The company utilizes vaccine delivery platforms, including viral and self-amplifying mRNA [3]